These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Current Progress in CAR-T Cell Therapy for Solid Tumors. Ma S; Li X; Wang X; Cheng L; Li Z; Zhang C; Ye Z; Qian Q Int J Biol Sci; 2019; 15(12):2548-2560. PubMed ID: 31754328 [TBL] [Abstract][Full Text] [Related]
8. Non-viral engineering of NK cells. Hinnekens C; De Smedt SC; Fraire JC; Braeckmans K Biotechnol Adv; 2023 Nov; 68():108212. PubMed ID: 37454745 [TBL] [Abstract][Full Text] [Related]
9. Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives. Labbé RP; Vessillier S; Rafiq QA Viruses; 2021 Aug; 13(8):. PubMed ID: 34452392 [TBL] [Abstract][Full Text] [Related]
10. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift? Madden DL Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148 [TBL] [Abstract][Full Text] [Related]
11. Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors. Alcantara M; Du Rusquec P; Romano E Oncoimmunology; 2020 Jun; 9(1):1777064. PubMed ID: 32934880 [TBL] [Abstract][Full Text] [Related]
12. Emerging trends in gene-modified-based chimeric antigen receptor-engineered T-cellular therapy for malignant tumors: The lesson from leukemia to pediatric brain tumors. Lin WY; Chen YW; Lin CF; Yang YP; Wang ML; Hung KF; Huang PI; Lee YY; Chiou SH J Chin Med Assoc; 2020 Aug; 83(8):719-724. PubMed ID: 32773642 [TBL] [Abstract][Full Text] [Related]
13. Natural killer cells: the next wave in cancer immunotherapy. Chen X; Jiang L; Liu X Front Immunol; 2022; 13():954804. PubMed ID: 35967421 [TBL] [Abstract][Full Text] [Related]
14. The swinging pendulum of cancer immunotherapy personalization. Abraham TS; Snook AE Per Med; 2017 May; 14(3):259-270. PubMed ID: 29767586 [TBL] [Abstract][Full Text] [Related]
15. CAR-expressing NK cells for cancer therapy: a new hope. Xia J; Minamino S; Kuwabara K Biosci Trends; 2020 Nov; 14(5):354-359. PubMed ID: 32893255 [TBL] [Abstract][Full Text] [Related]
16. Cellular immunotherapy for malignant gliomas. Lin Y; Okada H Expert Opin Biol Ther; 2016 Oct; 16(10):1265-75. PubMed ID: 27434205 [TBL] [Abstract][Full Text] [Related]
17. Mass Spectrometry Advances and Perspectives for the Characterization of Emerging Adoptive Cell Therapies. Lombard-Banek C; Schiel JE Molecules; 2020 Mar; 25(6):. PubMed ID: 32204371 [TBL] [Abstract][Full Text] [Related]
18. How much does the hospital stay for infusion of anti-CD19 CAR-T cells cost to the French National Health Insurance? Huguet M; Raimond V; Kaltenbach E; Augusto V; Perrier L Bull Cancer; 2021 Dec; 108(12):1170-1180. PubMed ID: 34561025 [TBL] [Abstract][Full Text] [Related]
19. Value and affordability of CAR T-cell therapy in the United States. Fiorenza S; Ritchie DS; Ramsey SD; Turtle CJ; Roth JA Bone Marrow Transplant; 2020 Sep; 55(9):1706-1715. PubMed ID: 32474570 [TBL] [Abstract][Full Text] [Related]
20. Adoptive Cellular Transfer Immunotherapies for Cancer. Parsonidis P; Papasotiriou I Cancer Treat Res Commun; 2022; 32():100575. PubMed ID: 35679756 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]